bioRxivCancer Biology
IDH-Tau-EGFR triad defines the neovascular landscape of diffuse gliomas by controlling mesenchymal differentiation
R. Gargini, B. Segura-Collar, V. Garcia-Escudero, A. Romero-Bravo, B. Herranz, F. J. Nunez, D. Garcia-Perez, A. Ayuso-Sacido, J. Seoane, J. M. Sepulveda-Sanchez, A. Hernandez-Lain, M. G. Castro, R. Garcia-Escudero, J. Avila, P. Sanchez-Gomez, J. Gutierrez-Guaman, A. Perez-Nunez
Abstract
Classification of gliomas as wild-type or mutant IDH1/2 tumors has profound clinical implications. However, how these two groups of gliomas progress, in a microenvironment-dependent manner, is still a pending question. Here we describe that the expression of Tau is epigenetically induced by mutant IDH1/2, whereas is almost absent from tumors with EGFR/PTEN mutations. Moreover, Tau (MAPT) expression is inversely correlated with overall survival in EGFR-amplified gliomas. Using orthotopic EGFR-related models, we have observed that Tau overexpression or microtubule stabilizers impair the mesenchymal transformation of glioma cells, with profound changes in tumor vasculature and a significant decrease in tumor burden. However, epithelial-to-mesenchymal transformed EGFR-mutant cells, acting as pericytes, induce neo-vasculogenesis and favor aggressive glioma growth, a process that is no longer sensitive to Tau. Altogether our data indicate that the genomic background controls glioma aggressiveness by modifying the vascular microenvironment. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=120 SRC="FIGDIR/small/541326v1_ufig1.gif" ALT="Figure 1"> View larger version (56K): org.highwire.dtl.DTLVardef@1c4b33forg.highwire.dtl.DTLVardef@d3f636org.highwire.dtl.DTLVardef@1c957c1org.highwire.dtl.DTLVardef@1a04a0d_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The genetic status of IDH1/2 and EGFR dictates the vascular landscape and the progression of gliomas
B. Segura-Collar, M. Garranzo-Asensio, … P. Sanchez-Gomez·bioRxiv·Sep 21, 2020
- Immune profiling of gliomas reveals a connection with Tau function and the tumor vasculature.
P. Sanchez-Gomez, J. M. Sepulveda-Sanchez, … M. C. Martin-Soberon·bioRxiv·Jul 17, 2020
- Low- and high-grade glioma endothelial cells differentially regulate tumor growth
S. D. Muthukrishnan, H. Qi, … H. I. Kornblum·bioRxiv·Jul 7, 2023
- Therapy-induced transdifferentiation promotes glioma growth independent of EGFR signaling
- Endothelin Signaling via EDNRB receptor Reduces Proliferation and Promotes Proneural-to-Mesenchymal Transition in Gliomas
Donovan Pineau, Leonor Garcia, … Jean‐Philippe Hugnot·Molecular OncologyPeer-reviewed·Apr 23, 2026
- Spatially resolved gene expression and tumour-microenvironment interactions across malignant transformation in IDH-mutant glioma
Alyona Ivanova, Shamini Ayyadhury, … Sunit Das·bioRxiv·Sep 16, 2026